RNAi leader Al­ny­lam inks col­lab­o­ra­tion pact with start­up; GV's Rosana Kapeller joins Schrödinger board

→ Eight months af­ter putting to­geth­er its $30 mil­lion A round, biotech start­up CAMP4 has inked a new col­lab­o­ra­tion with RNAi trend­set­ter Al­ny­lam. The two com­pa­nies plan to work to­geth­er to iden­ti­fy new drug tar­gets for an undis­closed rare liv­er dis­ease. CAMP4 CEO Josh Man­del-Brehm says his com­pa­ny will do the ini­tial dis­cov­ery work with Al­ny­lam tak­ing over any de­vel­op­ment work. The pact comes with an undis­closed up­front and mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER